The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to givinostat, an oral histone deacetylase inhibitor (HDACi) developed by Italfarmaco S.p.A., for the treatment of polycythemia vera (PV), a rare hematologic malignancy. This designation aims to expedite the development and review of drugs that address serious conditions with unmet medical needs. PV […]